Skip to content
Screener

Ironwood Pharmaceuticals IRWD Gross margin

Discontinued — last reported Q4 '20

Gross margin at other companies

Ardelyx logo
ArdelyxARDX
94.4%+9.6pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
93.4%+3.7pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
98.2%-0.7pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
98.2%-0.3pp
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
89.4%-0.2pp
Scilex Holding Company logo
Scilex Holding CompanySCLX
59.7%-12.3pp

Other financials

Income statement

See full
Revenue$113.0M+32.6%
Operating income$79.3M+75.0%
Net income$51.3M+117%
EPS (diluted)$0.31+121%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$11.9M-94.4%
Total equity-$161.8M+47.5%
Total assets$285.1M-16.9%

Cash flow

See full
Operating cash flow$58.3M—
CapEx-—
Free cash flow$74.6M+390%

Valuation

See full
Market cap$713.84M+427%
Enterprise value$646.58M+152%
P/E5.5×—
P/S1.8×+1.4×

Profitability

See full
Operating margin60.1%+36.4pp
Net margin33.4%+31.1pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity0×-0.5×
Current ratio6.1×+5.2×

Where this comes from

Calculated from Ironwood Pharmaceuticals’s reported figures.

gross profit/total revenue=99.2%

Based on trailing twelve months.

The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 16, 2023. Open the filing →

Filed
Feb 16, 2023
Fiscal year
FY2022
Accession
0001558370-23-001462

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.